Harvard Apparatus Regenerative Technology (HRGN) Q2 2024 earnings summary

Executive summary

• Harvard Apparatus Regenerative Technology is a clinical-stage biotech company focused on regenerative medicine for GI tract disorders and longevity supplements, with two operating segments: Regenerative Biotech and Longevity Products.

• The company launched longevity product sales in the Great China Region in Q3 2023 and continues to develop its esophageal implant, with ongoing but delayed patient recruitment for its FDA-approved phase 1 clinical trial.

• Operations are funded primarily through equity and debt financings, with a recent $1.5M private placement and a $0.5M bridge note from the CEO.

• As of June 30, 2024, the company had $0.1M in cash and an accumulated deficit of $96.5M, raising substantial doubt about its ability to continue as a going concern without additional capital.

Financial highlights

• Product revenue was $56,000 for Q2 2024 and $113,000 for the six months ended June 30, 2024, all from longevity products; no revenue was generated prior to Q3 2023.

• Net loss for Q2 2024 was $2.5M, compared to $2.6M in Q2 2023; net loss for the six months ended June 30, 2024 was $4.5M, down from $5.5M in the prior year period.

• Operating expenses for Q2 2024 were $2.5M, a 4% decrease year-over-year; for the six months, operating expenses were $4.6M, down 17% year-over-year.

• General and administrative expenses in Q2 2024 increased 64% year-over-year to $1.7M, mainly due to $0.5M in one-time offering costs.

• Cash used in operating activities was $2.3M for the six months ended June 30, 2024, compared to $2.6M in the prior year period.

Outlook and guidance

• Management expects continued operating losses and negative cash flows for 2024 and future years.

• Current cash and recent equity financing are expected to fund operations into Q3 2024; additional capital is required to avoid curtailing or ceasing operations.

• The company is actively seeking further equity, debt, or strategic financing, but there is no assurance of success.